Kenya - anglès - Pharmacy and Poisons Board

medisel kenya limited p.o box 540-01000 - griseofulvin - tablet - griseofulvin 125mg - griseofulvin

Estats Units - anglès - NLM (National Library of Medicine)

cipla usa inc. - griseofulvin (unii: 32hrv3e3d5) (griseofulvin - unii:32hrv3e3d5) - griseofulvin oral suspension is indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy, hair and nails, namely: tinea corporis tinea pedis tinea cruris tinea barbae tinea capitis tinea unguium when caused by one or more of the following species of fungi: epidermophyton floccosum microsporum audouinii microsporum canis microsporum gypseum trichophyton crateriformis trichophyton gallinae trichophyton interdigitalis trichophyton megnini trichophyton mentagrophytes trichophyton rubrum trichophyton schoenleini trichophyton sulphureum trichophyton tonsurans trichophyton verrucosum note: prior to therapy, a dermatophyte should be identified as responsible for the infection. prior to initiating treatment, appropriate specimens for laboratory testing (koh preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis. griseofulvin is not effective in the following: bacterial infections                             coccidioidomycosis candid

Kenya - anglès - Pharmacy and Poisons Board

universal corporation limited club road plot no.13777 p.o.box 1748-00902 kikuyu - griseofulvin bp - tablet - griseofulvin bp 250mg tablet - antifungals for systemic use

Estats Units - anglès - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - griseofulvin (unii: 32hrv3e3d5) (griseofulvin - unii:32hrv3e3d5) - griseofulvin is indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy, hair and nails, namely:     tinea corporis     tinea pedis     tinea cruris     tinea barbae     tinea capitis tinea unguium when caused by one or more of the following species of fungi:  epidermophyton floccosum  microsporum audouinii  microsporum canis  microsporum gypseum  trichophyton crateriform  trichophyton gallinae  trichophyton interdigitalis  trichophyton megnini  trichophyton mentagrophytes  trichophyton rubrum  trichophyton schoenleini  trichophyton sulphureum  trichophyton tonsurans  trichophyton verrucosum note: prior to therapy, a dermatophyte should be identified as responsible for the infection. prior to initiating treatment, appropriate specimens for laboratory testing (koh preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis. griseofulvin is not effective in the following: bacterial infections coccidioidomycosis candidiasis (moniliasis) north american blastomycosis histoplasmosis cryptococcosis (torulosis) actinomycosis tinea versicolor sporotrichosis nocardiosis chromoblastomycosis the use of this drug is not justified in minor or trivial dermatophyte infections which will respond to topical agents alone. griseofulvin is contraindicated in patients with porphyria or hepatocellular failure, and in individuals with a history of hypersensitivity to griseofulvin. griseofulvin may cause fetal harm when administered to a pregnant woman. two published cases of conjoined twins have been reported in patients taking griseofulvin during the first trimester of pregnancy, therefore, griseofulvin is contraindicated in women who are or may become pregnant during treatment. women taking estrogen-containing oral contraceptives may be at increased risk of becoming pregnant while on griseofulvin (see also precautions, drug interactions ). if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. although no direct causal relationship has been established, spontaneous abortion has been reported rarely coincident with the use of griseofulvin. note: the maximum recommended human dose (mrhd) was set at 500 mg/day for the multiple of human exposure calculations performed in this label. if higher doses than 500 mg/day were used clinically, then the multiple of human exposure would be correspondingly reduced for that dose. for example, if a 1000 mg/day dose was administered to an individual, then the multiple of human exposure would be reduced by a factor of 2. griseofulvin has been shown to be embryotoxic and teratogenic in pregnant rats when given at a daily oral dose of 250 mg/kg/day [4x the maximum recommended human dose (mrhd) based on body surface area (bsa)]. griseofulvin also has been shown to be embryotoxic and teratogenic in pregnant cats treated weekly with griseofulvin at doses of 500 to 1000 mg/week. there are reports of teratogenicity in a golden retriever when doses of 750 mg/day [1.2x the mrhd based on bsa] were administered for four weeks prior to and throughout the pregnancy, and in a study in which beagles were administered 35 mg/kg/day [1.9x the mrhd based on bsa] for intervals from one week up to the entire gestation period. teratogenicity was also seen in mice when griseofulvin was administered in doses equivalent to 5g/kg/day [40x the mrhd based on bsa] for 2 consecutive days at various stages of the pregnancy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - griseofulvin, quantity: 500 mg - tablet - excipient ingredients: sodium lauryl sulfate; povidone; maize starch; potato starch; microcrystalline cellulose; magnesium stearate - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Kenya - anglès - Pharmacy and Poisons Board

biodeal laboratories ltd p.o. box 32040 nairoki kenya - griseofulvin b.p. - tablet - griseofulvin b.p.125mg - antifungals for systemic use

Kenya - anglès - Pharmacy and Poisons Board

biodeal laboratories ltd p.o. box 32040 nairoki kenya - griseofulvin b.p. - tablet - griseofulvin b.p.250mg - antifungals for systemic use

Kenya - anglès - Pharmacy and Poisons Board

umedica laboratories pvt ltd plot no. 221 lind phase g.i.d.c. vapi - 396195 - griseofulvin - tablet - griseofulvin 125 mg - antifungals for systemic use

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hovid berhad - griseofulvin -

Estats Units - anglès - NLM (National Library of Medicine)

chartwell rx, llc. - griseofulvin (unii: 32hrv3e3d5) (griseofulvin - unii:32hrv3e3d5) - major indications for griseofulvin oral suspension, usp are: tinea capitis (ringworm of the scalp) tinea corporis (ringworm of the body) tinea pedis (athlete's foot) tinea unguium (onychomycosis; ringworm of the nails) tinea cruris (ringworm of the thigh) tinea barbae (barber’s itch) griseofulvin oral suspension, usp inhibits the growth of those genera of fungi that commonly cause ringworm infections of the hair, skin, and nails, such as: trichophyton rubrum trichophyton tonsurans trichophyton mentagrophytes trichophyton interdigitalis trichophyton verrucosum trichophyton sulphureum trichophyton schoenleini microsporum audouini microsporum canis microsporum gypseum epidermophyton floccosum trichophyton megnini trichophyton gallinae trichophyton crateriform note: prior to ther